Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Malaria Vaccines
Research from A.A. Siddiqui et al has provided new information about malaria vaccines
March 12th, 2008
"Despite the immense global efforts, the malaria vaccine is not yet available and requires the identification of newer target molecules. Since tryptophan-rich proteins of P. yoelii have been proposed as vaccine candidates, we describe here the expression, purification and immunological characterization of a 55 kDa Plasmodium vivax tryptophan- and alanine-rich antigen (PvTARAg55)," scientists in New Delhi, India report. "This protein consists of 480 aa residues with a calculated molecular mass of 55.0 kDa. It shows 42% aa sequence identity (64% homology) with PyPAg1 of P. yoelii and shares positional conservation of tryptophan residues. Sequence analysis of PvTARAg55...
Source: Vaccine Weekly (2008-03-12)
|
